Enzon Pharmaceuticals Inc  

(Public, NASDAQ:ENZN)   Watch this stock  
Find more results for ENZN
1.10
0.00 (0.00%)
Jul 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.78 - 2.09
Open     -
Vol / Avg. 0.00/717,254.00
Mkt cap 48.50M
P/E 2.07
Div/yield 0.45
EPS 0.53
Shares 44.09M
Beta 0.94
Inst. own 72%
Aug 4, 2014
Q2 2014 ENZON PHARMACEUTICALS INC Earnings Release (Estimated) Add to calendar
May 28, 2014
ENZON PHARMACEUTICALS INC Annual Shareholder Meeting
May 9, 2014
Q1 2014 ENZON PHARMACEUTICALS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 94.94% 52.62%
Operating margin 94.34% 52.65%
EBITD margin - 67.16%
Return on average assets 306.00% 17.54%
Return on average equity 359.24% 43.88%
Employees 1 -
CDP Score - -

Address

20 KINGSBRIDGE ROAD
PISCATAWAY, NJ 08854
United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company�s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.

Officers and directors

George W. Hebard III Interim Principal Executive Officer and Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Richard L. Feinstein Principal Financial Officer, Vice President - Finance
Age: 70
Bio & Compensation  - Reuters
Andrew D Rackear J.D. Chief Compliance Officer, General Counsel, Secretary & Head of Human Resources
Age: 59
Bio & Compensation  - Reuters
Jonathan N. Christodoro Director
Age: 36
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Director
Age: 36
Bio & Compensation  - Reuters
Jennifer McNealey Director
Bio & Compensation  - Reuters